Welcome to our dedicated page for Usana Health Sciences SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. (NYSE: USNA) files a range of documents with the U.S. Securities and Exchange Commission that provide detail on its nutrition-focused business, financial condition, and governance. This page centralizes those SEC filings and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
USANA’s current reports on Form 8-K include disclosures about preliminary financial results, updated net sales guidance, and leadership transitions, such as changes in the Chief Executive Officer role. Other 8-K filings describe credit agreements, financial covenants, and the posting of Management Commentary documents and conference call details related to quarterly results. These filings complement the company’s earnings releases and provide context on how management views performance in its direct selling and direct-to-consumer segments.
Investors can also use this page to access USANA’s periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, where available. These documents typically contain segment information, risk factor discussions, and explanations of non-GAAP measures such as Adjusted EBITDA and Adjusted diluted earnings per share, which USANA references in its communications.
Stock Titan’s platform enhances these filings with AI-generated highlights that explain key sections, summarize complex tables, and surface notable items such as changes in outlook, capital structure, or significant agreements. Users can quickly locate information on topics like net sales trends, credit facilities, or integration costs related to acquisitions such as Hiya, and can review insider-related disclosures when Forms 3, 4, or 5 are filed. Real-time updates from EDGAR help ensure that new USANA filings appear promptly with concise explanations.
USANA Health Sciences director Timothy E. Wood reported equity transactions involving restricted stock units and common stock of USNA. On January 22, 2026, 1,058 restricted stock units were converted into an equal number of shares of common stock at an exercise price of $0, increasing his directly held common shares to 10,085.
On the same date, he disposed of 265 shares of common stock at a price of $22.51 per share, leaving 9,820 common shares held directly after the reported transactions. Following the RSU conversion, he reported 1,057 restricted stock units beneficially owned. The filing notes that each restricted stock unit represents a contingent right to receive one share of USNA common stock, with these RSUs vesting 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Frederic J. Winssinger reported the vesting and conversion of 1,058 restricted stock units into an equal number of USANA common shares on January 22, 2026. These shares were acquired at a stated price of $0 per share, reflecting the nature of restricted stock units as equity awards rather than open‑market purchases.
After this transaction, Winssinger directly held 7,044 shares of USANA common stock and 1,057 restricted stock units. The footnotes explain that each restricted stock unit represents the right to receive one share of common stock, and that this RSU grant vests in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Nixon J. Scott reported an equity award transaction. On January 22, 2026, 1,058 restricted stock units (RSUs) were converted into 1,058 shares of USANA common stock at an exercise price of $0.00 per share, reflecting the nature of RSUs as stock-based compensation rather than a cash purchase.
After this transaction, Scott directly owned 8,756 shares of USANA common stock and 1,057 RSUs. The RSUs vest in four equal 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026, each representing the right to receive one share of USANA common stock when vested.
USANA Health Sciences director Peggie Pelosi reported equity transactions dated January 22, 2026. A block of 1,058 restricted stock units converted into 1,058 shares of common stock at an exercise price of
USANA Health Sciences (USNA) director Gilbert A. Fuller reported an equity award vesting and share issuance. On January 22, 2026, 1,058 restricted stock units (RSUs) were converted into 1,058 shares of USANA common stock at an exercise price of $0, reported with transaction code "M." Following this transaction, Fuller directly owned 1,058 shares of common stock and 1,057 RSUs.
The RSUs vest in four equal installments of 25% each on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026. Each RSU represents a contingent right to receive one share of USANA common stock, reflecting a standard director equity compensation structure.
USANA Health Sciences director Fleming John Turman reported the vesting and settlement of restricted stock units into common shares. On January 22, 2026, 1,058 restricted stock units were converted into 1,058 shares of USANA common stock at a price of $0 per share, reflecting the nature of RSUs as equity compensation rather than a market purchase.
After this transaction, Turman directly owned 5,623 shares of USANA common stock and 1,057 restricted stock units. The RSUs vest in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026, illustrating a staggered equity incentive structure tied to ongoing service.
USANA Health Sciences director Ding Xia reported stock transactions related to vesting equity awards. On January 22, 2026, 1,058 restricted stock units converted into the same number of USANA common shares at an exercise price of $0.00. These shares came from previously granted equity that vests in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
On the same day, 392 common shares were disposed of at $22.51 per share in a transaction coded "F," which typically reflects shares withheld to cover taxes on the vesting. After these transactions, Ding Xia directly held 6,584 shares of USANA common stock and 1,057 restricted stock units as derivative securities.
Dimensional Fund Advisors LP reported its holdings in USANA Health Sciences Inc. common stock as of 12/31/2025 on an amended Schedule 13G. The firm reported beneficial ownership of 848,452 shares, representing 4.6% of USANA’s outstanding common stock, which is at or below the 5% reporting threshold.
Dimensional reported sole voting power over 829,834 shares and sole dispositive power over the full 848,452 shares, with no shared voting or dispositive power. The filing explains that all securities are actually owned by various funds and accounts it advises (the “Funds”), and that Dimensional may be deemed a beneficial owner solely because it has voting and/or investment power for those Funds.
Dimensional explicitly disclaims beneficial ownership of the shares, stating that the holdings are managed in the ordinary course of business and not for the purpose of changing or influencing control of USANA.
BlackRock, Inc. has filed an amended Schedule 13G reporting a passive ownership stake in USANA Health Sciences Inc. common stock. BlackRock reports beneficial ownership of 799,296 shares, representing 4.4% of USANA’s outstanding common stock as of the event date December 31, 2025. It has sole voting power over 788,094 shares and sole dispositive power over 799,296 shares, with no shared voting or dispositive power. The filing states that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of USANA. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of the outstanding common shares through BlackRock.
USANA Health Sciences, Inc. reported that it has issued a press release with preliminary net sales for the full fiscal year ended January 3, 2026. The company also provided net sales guidance for its currently expected financial results for the fiscal year ending January 2, 2027. This information is furnished under Items 2.02 and 7.01 and is attached as Exhibit 99.1. The company states that this information is being furnished rather than filed under the Exchange Act and is not incorporated by reference into Securities Act registration statements.
FAQ
What is the current stock price of Usana Health Sciences (USNA)?
What is the market cap of Usana Health Sciences (USNA)?
